Cargando…

Clinical significance of troponin elevations in acute decompensated diabetes without clinical acute coronary syndrome

BACKGROUND: Elevation of cardiac troponin has been documented in multiple settings without acute coronary syndrome. However, its impact on long-term cardiac outcomes in the context of acute decompensated diabetes remains to be explored. METHODS: We performed a retrospective analysis of 872 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Eubanks, Anthony, Raza, Farhan, Alkhouli, Mohamad, Glenn, April N, Homko, Carol, Kashem, Abul, Bove, Alfred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549932/
https://www.ncbi.nlm.nih.gov/pubmed/23270513
http://dx.doi.org/10.1186/1475-2840-11-154
_version_ 1782256501984854016
author Eubanks, Anthony
Raza, Farhan
Alkhouli, Mohamad
Glenn, April N
Homko, Carol
Kashem, Abul
Bove, Alfred
author_facet Eubanks, Anthony
Raza, Farhan
Alkhouli, Mohamad
Glenn, April N
Homko, Carol
Kashem, Abul
Bove, Alfred
author_sort Eubanks, Anthony
collection PubMed
description BACKGROUND: Elevation of cardiac troponin has been documented in multiple settings without acute coronary syndrome. However, its impact on long-term cardiac outcomes in the context of acute decompensated diabetes remains to be explored. METHODS: We performed a retrospective analysis of 872 patients admitted to Temple University Hospital from 2004–2009 with DKA or HHS. Patients were included if they had cardiac troponin I (cTnI) measured within 24 hours of hospital admission, had no evidence of acute coronary syndrome and had a follow up period of at least 18 months. Of the 264 patients who met the criteria, we reviewed the baseline patient characteristics, admission labs, EKGs and major adverse cardiovascular events during the follow up period. Patients were categorized into two groups with normal and elevated levels of cardiac enzymes. The composite end point of the study was the occurrence of a major cardiovascular event (MACE) during the follow up period and was compared between the two groups. RESULTS: Of 264 patients, 24 patients were found to have elevated cTnI. Compared to patients with normal cardiac enzymes, there was a significant increase in incidence of MACE in patients with elevated cTnI. In a regression analysis, which included prior history of CAD, HTN and ESRD, the only variable that independently predicted MACE was an elevation in cTnI (p = 0.044). Patients with elevated CK-MB had increased lengths of hospitalization compared to the other group (p < 0.001). CONCLUSIONS: Elevated cardiac troponin I in patients admitted with decompensated diabetes and without evidence of acute coronary syndrome, strongly correlate with a later major cardiovascular event. Thus, elevated troponin I during metabolic abnormalities identify a group of patients at an increased risk for poor long-term outcomes. Whether these patients may benefit from early detection, risk stratification and preventive interventions remains to be investigated.
format Online
Article
Text
id pubmed-3549932
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35499322013-01-24 Clinical significance of troponin elevations in acute decompensated diabetes without clinical acute coronary syndrome Eubanks, Anthony Raza, Farhan Alkhouli, Mohamad Glenn, April N Homko, Carol Kashem, Abul Bove, Alfred Cardiovasc Diabetol Original Investigation BACKGROUND: Elevation of cardiac troponin has been documented in multiple settings without acute coronary syndrome. However, its impact on long-term cardiac outcomes in the context of acute decompensated diabetes remains to be explored. METHODS: We performed a retrospective analysis of 872 patients admitted to Temple University Hospital from 2004–2009 with DKA or HHS. Patients were included if they had cardiac troponin I (cTnI) measured within 24 hours of hospital admission, had no evidence of acute coronary syndrome and had a follow up period of at least 18 months. Of the 264 patients who met the criteria, we reviewed the baseline patient characteristics, admission labs, EKGs and major adverse cardiovascular events during the follow up period. Patients were categorized into two groups with normal and elevated levels of cardiac enzymes. The composite end point of the study was the occurrence of a major cardiovascular event (MACE) during the follow up period and was compared between the two groups. RESULTS: Of 264 patients, 24 patients were found to have elevated cTnI. Compared to patients with normal cardiac enzymes, there was a significant increase in incidence of MACE in patients with elevated cTnI. In a regression analysis, which included prior history of CAD, HTN and ESRD, the only variable that independently predicted MACE was an elevation in cTnI (p = 0.044). Patients with elevated CK-MB had increased lengths of hospitalization compared to the other group (p < 0.001). CONCLUSIONS: Elevated cardiac troponin I in patients admitted with decompensated diabetes and without evidence of acute coronary syndrome, strongly correlate with a later major cardiovascular event. Thus, elevated troponin I during metabolic abnormalities identify a group of patients at an increased risk for poor long-term outcomes. Whether these patients may benefit from early detection, risk stratification and preventive interventions remains to be investigated. BioMed Central 2012-12-27 /pmc/articles/PMC3549932/ /pubmed/23270513 http://dx.doi.org/10.1186/1475-2840-11-154 Text en Copyright ©2012 Eubanks et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Investigation
Eubanks, Anthony
Raza, Farhan
Alkhouli, Mohamad
Glenn, April N
Homko, Carol
Kashem, Abul
Bove, Alfred
Clinical significance of troponin elevations in acute decompensated diabetes without clinical acute coronary syndrome
title Clinical significance of troponin elevations in acute decompensated diabetes without clinical acute coronary syndrome
title_full Clinical significance of troponin elevations in acute decompensated diabetes without clinical acute coronary syndrome
title_fullStr Clinical significance of troponin elevations in acute decompensated diabetes without clinical acute coronary syndrome
title_full_unstemmed Clinical significance of troponin elevations in acute decompensated diabetes without clinical acute coronary syndrome
title_short Clinical significance of troponin elevations in acute decompensated diabetes without clinical acute coronary syndrome
title_sort clinical significance of troponin elevations in acute decompensated diabetes without clinical acute coronary syndrome
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549932/
https://www.ncbi.nlm.nih.gov/pubmed/23270513
http://dx.doi.org/10.1186/1475-2840-11-154
work_keys_str_mv AT eubanksanthony clinicalsignificanceoftroponinelevationsinacutedecompensateddiabeteswithoutclinicalacutecoronarysyndrome
AT razafarhan clinicalsignificanceoftroponinelevationsinacutedecompensateddiabeteswithoutclinicalacutecoronarysyndrome
AT alkhoulimohamad clinicalsignificanceoftroponinelevationsinacutedecompensateddiabeteswithoutclinicalacutecoronarysyndrome
AT glennapriln clinicalsignificanceoftroponinelevationsinacutedecompensateddiabeteswithoutclinicalacutecoronarysyndrome
AT homkocarol clinicalsignificanceoftroponinelevationsinacutedecompensateddiabeteswithoutclinicalacutecoronarysyndrome
AT kashemabul clinicalsignificanceoftroponinelevationsinacutedecompensateddiabeteswithoutclinicalacutecoronarysyndrome
AT bovealfred clinicalsignificanceoftroponinelevationsinacutedecompensateddiabeteswithoutclinicalacutecoronarysyndrome